US2019054153A1PendingUtilityA1
Sialylated glycoprotein compositions and uses thereof
Assignee: ULTRAGENYX PHARMACEUTICAL INCPriority: Mar 5, 2014Filed: Apr 2, 2018Published: Feb 21, 2019
Est. expiryMar 5, 2034(~7.6 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 3/00C12N 9/2468A61K 38/47C12Y 302/01031C12N 9/2402C12N 9/24A61K 45/06A61K 9/0019C12N 15/67
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present application relates to sialylated glycoprotein compositions and methods of their use in treating various conditions and disorders.
Claims
exact text as granted — not AI-modified1 .- 27 . (canceled)
28 . A method for treating mucopolysaccharidosis type 7 in a subject in need thereof, comprising administering to the subject a composition comprising a recombinant β-glucuronidase, wherein the recombinant β-glucuronidase is administered every other week by continuous intravenous infusion at a dose of 1 mg/kg to 8 mg/kg.
29 . The method of claim 28 , wherein the subject is a human.
30 . The method of claim 28 , wherein the recombinant β-glucuronidase is administered at a dose of 2 mg/kg to 6 mg/kg.
31 . The method of claim 28 , wherein the recombinant β-glucuronidase is administered at a dose of 4 mg/kg.
32 . The method of claim 28 , wherein the recombinant β-glucuronidase is administered concurrently with or following antihistamine therapy.Join the waitlist — get patent alerts
Track US2019054153A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.